Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 
 
 

Nomad, Bayer, Icon in biosimilars deal
October 2008
SHARING OPTIONS:

MUNICH, GermanyŚNomad Bioscience GmbH announced it entered a broad licensing agreement with Bayer Innovation GmbH and Icon Genetics group which provides Nomad access to Icon's proprietary technology platforms, including its transient expression technology magnICON, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The financial terms of the agreement were not disclosed.

"Icon Genetics' proprietary gene transfer systems provide a broad solution to the upstream part of manufacturing, and combined with Nomad downstream technologies, they should result in a superior fully integrated process for most of our intended product candidates," says Dr. Yuri Gleba, the founder of Nomad Bioscience. Prof. Dr. Gleba is also co-inventor of Icon's technologies as well as co-founder and managing director of Icon Genetics. DDN

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.